These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 36126606)

  • 1. Novel diaryl ether derivatives as InhA inhibitors: Design, synthesis and antimycobacterial activity.
    Abdelaziz OA; Othman DIA; Abdel-Aziz MM; Badr SMI; Eisa HM
    Bioorg Chem; 2022 Dec; 129():106125. PubMed ID: 36126606
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological evaluation of potent triclosan-derived inhibitors of the enoyl-acyl carrier protein reductase InhA in drug-sensitive and drug-resistant strains of Mycobacterium tuberculosis.
    Stec J; Vilchèze C; Lun S; Perryman AL; Wang X; Freundlich JS; Bishai W; Jacobs WR; Kozikowski AP
    ChemMedChem; 2014 Nov; 9(11):2528-37. PubMed ID: 25165007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First triclosan-based macrocyclic inhibitors of InhA enzyme.
    Rodriguez F; Saffon N; Sammartino JC; Degiacomi G; Pasca MR; Lherbet C
    Bioorg Chem; 2020 Jan; 95():103498. PubMed ID: 31855823
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 4-Aryl-1,4-Dihydropyridines as Potential Enoyl-Acyl Carrier Protein Reductase Inhibitors: Antitubercular Activity and Molecular Docking Study.
    Venugopala KN; Deb PK; Pillay M; Chopra D; Chandrashekharappa S; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Kandeel M; Venugopala R; Mohanlall V
    Curr Top Med Chem; 2021; 21(4):295-306. PubMed ID: 33138763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of thiourea-based derivatives as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan ŞD; Gündüz MG; Doğan H; Krishna VS; Lherbet C; Sriram D
    Eur J Med Chem; 2020 Aug; 199():112402. PubMed ID: 32417538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New coumarin linked thiazole derivatives as antimycobacterial agents: Design, synthesis, enoyl acyl carrier protein reductase (InhA) inhibition and molecular modeling.
    Kassem AF; Sabt A; Korycka-Machala M; Shaldam MA; Kawka M; Dziadek B; Kuzioła M; Dziadek J; Batran RZ
    Bioorg Chem; 2024 Sep; 150():107511. PubMed ID: 38870705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isatin-pyrimidine hybrid derivatives as enoyl acyl carrier protein reductase (InhA) inhibitors against Mycobacterium tuberculosis.
    Khalifa A; Khalil A; Abdel-Aziz MM; Albohy A; Mohamady S
    Bioorg Chem; 2023 Sep; 138():106591. PubMed ID: 37201321
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and anti-Mycobacterium tuberculosis evaluation of new thiazolidin-4-one and thiazolo[3,2-a][1,3,5]triazine derivatives.
    Younis MH; Mohammed ER; Mohamed AR; Abdel-Aziz MM; Georgey HH; Abdel Gawad NM
    Bioorg Chem; 2022 Jul; 124():105807. PubMed ID: 35487073
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Vitro Antimycobacterial Activity and Physicochemical Characterization of Diaryl Ether Triclosan Analogues as Potential InhA Reductase Inhibitors.
    Ibrahim TS; Taher ES; Samir E; M Malebari A; Khayyat AN; Mohamed MFA; Bokhtia RM; AlAwadh MA; Seliem IA; Asfour HZ; Alhakamy NA; Panda SS; Al-Mahmoudy AMM
    Molecules; 2020 Jul; 25(14):. PubMed ID: 32650556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis, Biological Evaluation and Molecular Docking Studies of New Pyrazolines as an Antitubercular and Cytotoxic Agents.
    Lokesh BVS; Prasad YR; Shaik AB
    Infect Disord Drug Targets; 2019; 19(3):310-321. PubMed ID: 30556506
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of potential inhibitors of
    Kamera S; Sharma VK; Prasad V B; Garlapati A
    J Biomol Struct Dyn; 2024 Sep; 42(15):7957-7971. PubMed ID: 37526169
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of gallic acid formazans as novel enoyl acyl carrier protein reductase inhibitors for the treatment of tuberculosis.
    Saharan VD; Mahajan SS
    Bioorg Med Chem Lett; 2017 Feb; 27(4):808-815. PubMed ID: 28117201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Mycobacterium tuberculosis InhA: Design, synthesis and evaluation of new di-triclosan derivatives.
    Armstrong T; Lamont M; Lanne A; Alderwick LJ; Thomas NR
    Bioorg Med Chem; 2020 Nov; 28(22):115744. PubMed ID: 33007556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potent indolizine derivatives against Mycobacterial tuberculosis: In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies.
    Venugopala KN; Chandrashekharappa S; Deb PK; Al-Shar'i NA; Pillay M; Tiwari P; Chopra D; Borah P; Tamhaev R; Mourey L; Lherbet C; Aldhubiab BE; Tratrat C; Attimarad M; Nair AB; Sreeharsha N; Mailavaram RP; Venugopala R; Mohanlall V; Morsy MA
    Int J Biol Macromol; 2024 Aug; 274(Pt 2):133285. PubMed ID: 38925196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of new anti-mycobacterial agents based on quinoline-isatin hybrids targeting enoyl acyl carrier protein reductase (InhA).
    Khaleel EF; Sabt A; Korycka-Machala M; Badi RM; Son NT; Ha NX; Hamissa MF; Elsawi AE; Elkaeed EB; Dziadek B; Eldehna WM; Dziadek J
    Bioorg Chem; 2024 Mar; 144():107138. PubMed ID: 38262087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tryptanthrin Analogues as Inhibitors of Enoyl-acyl Carrier Protein Reductase: Activity against Mycobacterium tuberculosis, Toxicity, Modeling of Enzyme Binding.
    Duca G; Pogrebnoi S; Boldescu V; Aksakal F; Uncu A; Valica V; Uncu L; Negres S; Nicolescu F; Macaev F
    Curr Top Med Chem; 2019; 19(8):609-619. PubMed ID: 30834838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme.
    Venugopala KN; Chandrashekharappa S; Deb PK; Tratrat C; Pillay M; Chopra D; Al-Shar'i NA; Hourani W; Dahabiyeh LA; Borah P; Nagdeve RD; Nayak SK; Padmashali B; Morsy MA; Aldhubiab BE; Attimarad M; Nair AB; Sreeharsha N; Haroun M; Shashikanth S; Mohanlall V; Mailavaram R
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):1472-1487. PubMed ID: 34210233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of novel and potent InhA direct inhibitors by ensemble docking-based virtual screening and biological assays.
    Zhang Q; Han J; Zhu Y; Yu F; Hu X; Tong HHY; Liu H
    J Comput Aided Mol Des; 2023 Dec; 37(12):695-706. PubMed ID: 37642861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of hydrazone containing thiadiazoles as Mycobacterium tuberculosis growth and enoyl acyl carrier protein reductase (InhA) inhibitors.
    Doğan H; Doğan ŞD; Gündüz MG; Krishna VS; Lherbet C; Sriram D; Şahin O; Sarıpınar E
    Eur J Med Chem; 2020 Feb; 188():112035. PubMed ID: 31951850
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of benzo[d]oxazol-2(3H)-ones derivatives as novel inhibitors of Mycobacterium tuberculosis InhA.
    Pedgaonkar GS; Sridevi JP; Jeankumar VU; Saxena S; Devi PB; Renuka J; Yogeeswari P; Sriram D
    Bioorg Med Chem; 2014 Nov; 22(21):6134-45. PubMed ID: 25282650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.